Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive therapy for multidrug-resistant tuberculosis contacts
2008-006765-82Phase 2Terminated
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- May 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of moxifloxacin, pyrazinamide and ethambutol in latent tuberculosis infection (LTBI) and multidrug-resistant tuberculosis (MDR-TB) (3 arms), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoints: Discontinuation rate and Safety. Started May 2009; status: terminated.
02
Drugs
moxifloxacinpyrazinamideethambutol
03
Conditions
latent tuberculosis infection (LTBI)multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on 2008-006765-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006765-82.